BenevolentAI SA
BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, a… Read more
BenevolentAI SA (BAI) - Total Liabilities
Latest total liabilities as of December 2023: €29.56 Million EUR
Based on the latest financial reports, BenevolentAI SA (BAI) has total liabilities worth €29.56 Million EUR as of December 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BenevolentAI SA - Total Liabilities Trend (2018–2023)
This chart illustrates how BenevolentAI SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BenevolentAI SA Competitors by Total Liabilities
The table below lists competitors of BenevolentAI SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Janel Corp
PINK:JANL
|
USA | $91.29 Million |
|
Team Young Advanced Technology Co Ltd
TWO:5345
|
Taiwan | NT$6.42 Million |
|
Vince Holding Corp
NYSE:VNCE
|
USA | $189.68 Million |
|
Scandinavian Investment Group A/S
CO:SIG
|
Denmark | Dkr122.60 Million |
|
AEON Biopharma, Inc.
NYSE MKT:AEON
|
USA | $28.61 Million |
|
Cannindah Resources Ltd
AU:CAE
|
Australia | AU$109.84K |
|
Coloray International Investment Co. Ltd
KQ:900310
|
Korea | ₩40.22 Billion |
Liability Composition Analysis (2018–2023)
This chart breaks down BenevolentAI SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BenevolentAI SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BenevolentAI SA (2018–2023)
The table below shows the annual total liabilities of BenevolentAI SA from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €29.56 Million | -7.49% |
| 2022-12-31 | €31.95 Million | +7.39% |
| 2021-12-31 | €29.75 Million | +16.79% |
| 2020-12-31 | €25.48 Million | -2.05% |
| 2019-12-31 | €26.01 Million | +165.11% |
| 2018-12-31 | €9.81 Million | -- |